GE Healthcare has received 510k clearance from the US Food and Drug Administration for CoreScan – an application that quantifies visceral adipose tissue (VAT) during body composition analysis, to help assess, manage and treat obesity-related disease.
CoreScan, a new application on GE Lunar iDXA body composition systems, uses a non-invasive, low-dose x-ray exam.
GE Healthcare said its iDXA systems provide total and regional body composition assessments of fat tissue, lean tissue and bone mineral content in an easy-to-interpret report.
Available for adults of almost every age and size, CoreScan reports from an iDXA exam can help healthcare professionals manage VAT and obesity-related disease – including hypertension, diabetes, dyslipidemia and metabolic syndrome.
GE Healthcare Lunar business general manager Laura Stoltenberg said as part of an iDXA body composition exam, CoreScan can help patients and physicians tailor individualized health and wellness plans while addressing the growing global danger of obesity-related disease.